Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

NCT ID: NCT07038629

Last Updated: 2026-01-07

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-01
• Study Completion Date: 2027-09-30

Brief Summary

This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma (ESCC). Aim to evaluate the efficacy and safety of Iparomlimab consolidation therapy following concurrent chemoradiation with S-1 in elderly patients with unresectable locally advanced ESCC.

Concurrent chemoradiation is the standard treatment for elderly esophageal cancer. However, the overall prognosis of patients still needs to be further improved. The emergence of immune checkpoint inhibitors has brought new hope for patients with ESCC. Iparomlimab can target both PD-1 and CTLA-4 immune inhibitory pathways simultaneously. Studies have shown that it can significantly improve the prognosis in the treatment of ESCC and has good tolerability. In elderly patients with ESCC, concurrent chemoradiation may potentially carry the risk of low treatment completion rate and significant toxicity. Therefore, this study aims to explore the efficacy and safety of Iparomlimab consolidation therapy following concurrent chemoradiotherapy in elderly patients with unresectable locally advanced ESCC.

In the study, the investigators plan to enroll 52 elderly subjects with locally advanced ESCC. After receiving radiotherapy combined with the S-1 regimen, patients will enter the screening period. The enrolled patients will receive Iparomlimab consolidation therapy for 1 year. The treatment efficacy and safety will be evaluated.

Conditions

Esophageal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Chemoradiation Plus Iparomlimab Consolidation

S1 + Radiotherapy+ Iparomlimab Consolidation:

Chemotherapy: S1 PO, 40~60mg，BID（d1-14，d22-35，two cycles); Radiation: Concurrent Radiation, 1.8Gy/f, 28f; Iparomlimab Consolidation: Iparomlimab IV infusion, 5mg/kg, q3w (Started within 8 weeks of completion of radiation)

Group Type: EXPERIMENTAL

S1

Intervention Type: DRUG

PO, 40\~60mg，BID（d1-14，d22-35，two cycles)

Iparomlimab

Intervention Type: DRUG

IV infusion, 5mg/kg, q3w (Started within 8 weeks of completion of radiation)

Radiation

Intervention Type: RADIATION

Concurrent Radiation, 1.8Gy/f, 28f;

Interventions

S1

PO, 40\~60mg，BID（d1-14，d22-35，two cycles)

Intervention Type: DRUG

Iparomlimab

IV infusion, 5mg/kg, q3w (Started within 8 weeks of completion of radiation)

Intervention Type: DRUG

Radiation

Concurrent Radiation, 1.8Gy/f, 28f;

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

1. Volunteered to participate, cooperated with follow-up visits;

2. Aged ≥ 70 years, both male and female;

3. Histologically confirmed cT1N2-3M0 or cT2-4bN0-3M0 or cT1-4bN0-3M1(supraclavicular lymph node metastasis) locally advanced ESCC (8th AJCC );

4. Presence of measurable and/or non-measurable lesions as defined by Japanese Classification of Esophageal Cancer (12th Edition);

5. Initial treatment: definitive concurrent chemoradiotherapy (radiotherapy: total dose 50.4 Gy, delivered in 28 fractions, 1.8 Gy per fraction, 5 times per week; chemotherapy: S-1: 40-60mg, BID, d1-14, d22-35, for a total of 2 cycles).

1. Radiotherapy: completed ≥ 25 fractions or more (i.e., radiotherapy dose ≥ 45 Gy), S-1chemotherapy: completed at least one cycle (d1-14);

2. Haven't received any previous systemic anti-tumor therapy before radiotherapy (including but not limited to systemic chemotherapy, radiotherapy, molecularly targeted drug therapy, immunotherapy, biologic therapy, topical therapy and other investigational treatment drugs);

6. ECOG performance status 0 or 1;

7. Provide fresh or archived tumour tissue samples within 6 months (fresh samples preferred) for biomarker analysis (e.g.PD-L1). Sample types are formalin-fixed, paraffin-embedded [FFPE] tumour tissue blocks or at least 5 unstained, 3-5 μm thick FFPE tumour tissue sections;

8. Expected survival of ≥ 3 months.

9. The function of major organs meets the following requirements:

1. Absolute neutrophil count (ANC) ≥ 1.5×10^9/L;

2. Platelets ≥ 100×10^9/L;

3. Hemoglobin ≥ 9g/dL;

4. Serum albumin ≥ 2.8g/dL;

5. Total bilirubin ≤ 1.5 × ULN, ALT, AST and/or ALP ≤ 2.5 × ULN;

6. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60mL/min;

7. International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5× ULN (subjects on stable doses of anticoagulation therapy, such as low molecular weight heparin or warfarin, and with INR within the expected therapeutic range of the anticoagulant can be screened);

10. Documented informed consent.

Exclusion Criteria

1. Surgery for esophageal cancer;

2. Esophageal fistulae due to infiltration of the primary tumor；

3. Risk of gastrointestinal bleeding, esophageal fistula or esophageal perforation;

4. Patients who developed ≥ grade 2 pneumonia after concurrent chemoradiotherapy with S-1;

5. Poor nutritional status, weight loss of ≥10% in the previous 2 months, with no significant improvement after nutritional intervention;

6. Major surgery or severe trauma within 4 weeks prior to first use of study drug;

7. Uncontrollable pleural effusion, pericardial effusion, or ascites that requires repeated drainage;

8. Received or receiving any of the following treatments in the past:

1. Anti-PD-1 or anti-PD-L1 antibody therapy, chemotherapy, radiotherapy or targeted therapy;

2. Participation in a study of an investigational agent or device within 4 weeks before the first dose of study treatment;

3. Systemic treatment with corticosteroids (>10 mg prednisone equivalent dose per day) or other immunosuppressive agents is required for 2 weeks before the first dose of study treatment(except for the use of corticosteroids for local inflammation of the esophagus and for the prevention of allergy and nausea and vomiting). Other special circumstances need to be communicated to the sponsor. Inhaled or topical steroids and adrenocorticotropic hormone replacement at doses >10mg/day prednisone efficacy dose are permitted if the patient does not have active autoimmune disease;

4. Received an anti-tumour vaccine or received a live vaccine within 4 weeks before the first dose of study treatment;

9. Any active autoimmune disease or history of autoimmune disease (e.g., interstitial pneumonitis, uveitis, enteritis, hepatitis, pituitary gland inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism); Except for patients with vitiligo or those who had asthma or allergies in childhood but did not need any intervention as adults; patients with autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone and type I diabetes mellitus treated with stable doses of insulin may be included;

10. Diagnosis of immunodeficiency, including positive HIV test, other acquired/congenital immunodeficiency diseases, organ transplantation and allogeneic bone marrow transplantation;

11. Diagnosis of uncontrolled cardiac clinical symptoms or disease such as: a. NYHA II or above heart failure; b. unstable angina; c. myocardial infarction within 1 year; d. clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;

12. Severe infections (CTCAE > grade 2), such as severe pneumonia requiring hospitalisation, bacteraemia, infectious co-morbidities, etc., within 4 weeks before the first use of study treatment; Baseline chest imaging suggestive of active lung inflammation, signs and symptoms of infection requiring oral or intravenous antibiotic treatment within 2 weeks before the first use of study treatment, except for prophylactic antibiotic use;

13. History of interstitial lung disease or non-infectious pneumonia, or pulmonary insufficiency ≥ grade 3 as confirmed by pulmonary function tests;

14. Active tuberculosis infection detected by history or CT examination, or history of active tuberculosis infection within 1 year before enrollment or more than 1 year previously without regular treatment;

15. Presence of active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C (hepatitis C antibody positive and HCV-RNA above the lower limit of detection);

16. Presence of abnormal sodium, potassium, and calcium laboratory test values greater than grade 1 within 2 weeks prior to randomisation that do not improve with treatment;

17. Known hypersensitivity to large protein preparations, or to any of the components of tirilizumab, or anaphylaxis, hypersensitivity, or contraindication to paclitaxel or cisplatin or to any of the components used within their preparations;

18. Previously diagnosed with any other malignancy before the first use of the investigational drug, except for malignancies with low risk of metastasis and death (5-year survival rate>90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.

19. As judged by the investigator, the subject has other factors that may lead to forced termination of the study midway.

• Minimum Eligible Age: 70 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanxi Province Cancer Hospital

OTHER

Sponsor Role: collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

Sponsor Role: collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wencheng Zhang, M.D.

Role: PRINCIPAL_INVESTIGATOR

Tianjin Cancer Hospital

Locations

Tianjin Cancer Hospital

Tianjin, Tianjin Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Wencheng Zhang, M.D.

Role: CONTACT

zhangwencheng@tjmuch.com

02223340123 ext. 1121

Linrui Gao, M.D.

Role: CONTACT

02223340123 ext. 1121

Facility Contacts

Wencheng Zhang, M.D.

Role: primary

zhangwencheng@tjmuch.com

02223340123 ext. 1121

Other Identifiers

E20250418

Identifier Type: -

Identifier Source: org_study_id